Clinical Trial Update: Clinical Pathway for Alzheimer's Disease in China (CPAD)

View source ↗

Summary

This update notes that the CPAD (Clinical Pathway for Alzheimer's Disease in China) trial conducted by Peking University has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Snippet

Sponsor: Peking University | Conditions: Mild Cognitive Impairment, Alzheimer's Disease | Status: COMPLETED